Kraematon Investment Advisors’s Beam Therapeutics BEAM Stock Holding History

Kraematon Investment Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,915	Closed	-$253K	–	79
2023 Q2	$253K	Buy	+7,915	New	+$257K	0.28%	71
2023 Q1	–	Sell	-5,515	Closed	-$216K	–	93
2022 Q4	$216K	Hold	5,515	–	–	0.23%	78
2022 Q3	$263K	Hold	5,515	–	–	0.34%	71
2022 Q2	$213K	Hold	5,515	–	–	0.25%	79
2022 Q1	$316K	Buy	5,515 +100	+2%	+$6.56K	0.3%	68
2021 Q4	$432K	Buy	+5,415	New	+$464K	0.39%	62

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Kraematon Investment Advisors's BEAM Position: Q3 2023 in Review

Kraematon Investment Advisors sold out of Beam Therapeutics (BEAM) in Q3 2023, closing a stake of 7,915 shares — an estimated $253K sold.

Kraematon Investment Advisors first reported a position in BEAM in Q4 2021 and held it in 6 quarters. The position peaked at $432K in Q4 2021. 194 funds tracked by Wall St. Rank hold BEAM as of Q3 2023.

Kraematon Investment Advisors reported no remaining Beam Therapeutics position as of Q3 2023 after selling out during the quarter.
Kraematon Investment Advisors sold 7,915 Beam Therapeutics shares in Q3 2023, an estimated $253K.
Kraematon Investment Advisors first reported a position in Beam Therapeutics in Q4 2021 and held it in 6 quarters.
Kraematon Investment Advisors's Beam Therapeutics position peaked at $432K in Q4 2021.
194 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2023.

Based on Kraematon Investment Advisors's 13F filing for Q3 2023, filed 1 Nov 2023.